Jubilant Therapeutics Unveils Dual-Target MPN Drug Data Ahead of ASH 2026

YARDLEY, PA – November 10, 2026

Blood cancers like essential thrombocythemia (ET) often exist in a clinical gray area. For many, it is a chronic condition managed with decades-old therapies. But for a critical subset of patients, the standard systems of care eventually break down. Resistance builds, toxicities mount, and the looming threat of thrombosis or disease progression becomes a daily reality. On Tuesday, clinical-stage biopharmaceutical company Jubilant Therapeutics signaled a potential shift in this paradigm, announcing that early data for its novel asset, JBI-802, has secured a coveted oral presentation at the upcoming 68th American Society of Hematology (ASH) Annual Meeting in December.

The Mechanics of a Dual Attack

To understand why hematologists are paying attention, we have to look at the architecture of the drug. JBI-802 is not a traditional blunt-force chemotherapy. It is a first-in-class, orally administered dual inhibitor targeting two specific epigenetic enzymes: lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6), which operate together within the CoREST complex.

In the high-stakes environment of myeloproliferative neoplasms (MPNs), abnormal megakaryocytes overdrive the production of platelets. Single-agent LSD1 inhibitors are already moving through the clinic to disrupt this process. However, Jubilant’s approach is fundamentally systemic. By simultaneously inhibiting HDAC6—an enzyme involved in protein trafficking and immune responses—alongside LSD1, JBI-802 aims to dismantle the CoREST repressor complex entirely.

This dual-pronged attack theoretically prevents the cancer cells from developing rapid resistance pathways, a common failure point in single-target oncology drugs. "We are pleased to have the clinical results for JBI-802 selected for oral presentation at ASH," said Daniel O'Connor, President and Chief Executive Officer of Jubilant Therapeutics. "The abstract data show rapid platelet reductions with concurrent control of leukocytosis across disease subtypes and driver mutations, and responses have been durable to date."

Bridging the Gap in Standard of Care

The true value of any medical innovation lies in its ability to solve an existing human problem. For ET patients, the first line of defense is usually hydroxyurea, an older cytoreductive therapy that effectively lowers blood counts but carries a heavy burden of side effects, including severe fatigue, gastrointestinal distress, and painful leg ulcers. Roughly 20 to 30 percent of patients eventually become resistant or intolerant to it.

When hydroxyurea fails, the fallback options are fraught with compromises. Anagrelide carries cardiovascular risks. Ruxolitinib, while effective for symptom control in some MPNs, can induce severe cytopenias and increase infection risks. Even the recently FDA-approved ropeginterferon alfa-2b, while a massive step forward, can take up to a year to achieve optimal responses and brings its own suite of interferon-related side effects.

This is where JBI-802’s Phase 1 data, though preliminary, alters the conversation. According to the abstract released ahead of ASH, all eight patients who initiated treatment at the 15 mg dose achieved greater than 50 percent platelet reduction or complete normalization within just three weeks. The median time to response was a staggering 15 days. For a patient living under the constant neurological and vascular threat of a platelet surge, a two-week turnaround to normalization is not just a clinical endpoint; it is a rapid restoration of safety.

Furthermore, the drug demonstrated concurrent control of leukocytosis—an elevated white blood cell count that often exacerbates inflammatory and thrombotic risks in MPN patients. Seven of the 11 patients presenting with leukocytosis at the 15 mg dose level achieved a complete hematologic response.

A Corporate Milestone on the Big Stage

For Jubilant Therapeutics, a privately held biotech headquartered in Yardley, Pennsylvania, securing an oral presentation at ASH—the premier global hematology conference—is a significant corporate validation. It elevates JBI-802 from an interesting preclinical concept to a highly visible clinical contender.

The biopharma sector is notoriously unforgiving to novel mechanisms of action that fail to clear early safety hurdles. Epigenetic modifiers, in particular, have historically struggled with off-target toxicities. Yet, Jubilant reported no dose-limiting toxicities across its 5 mg, 7 mg, and 15 mg cohorts as of the June 30, 2026, data cutoff.

If these safety profiles hold, JBI-802 could establish an entirely new therapeutic class, not just for ET, but potentially for a broader spectrum of thrombocytosis-predominant myeloid malignancies. The company is also advancing JBI-3041, a PAD4 inhibitor for autoimmune diseases, signaling a broader ambition to leverage its structure-based drug design platform across multiple complex systemic failures. Jubilant will host an investor event on December 14 to detail the Phase 1 findings, a clear move to capitalize on the momentum and likely attract the capital necessary for expansive Phase 2 trials.

Looking Past the Abstract

As with all early-stage data, forensic scrutiny is required. While a 15-day median response time and durable control out to 46 weeks in some patients are remarkable, the sample sizes are undeniably small. Eight patients at the target dose is enough to prove a biological concept, but it is not enough to define a drug’s ultimate market reality.

Independent hematologists will be looking closely at the full data presentation on December 14. The absence of dose-limiting toxicities is a specific regulatory term; it does not mean an absolute absence of side effects. The medical community will want to see the granular breakdown of lower-grade adverse events. Analysts will question if there are subtle epigenetic off-target effects, and how the drug interacts with the complex inflammatory environment of a patient who has already failed multiple prior therapies.

Moreover, the durability of these responses will be tested as the trial matures. Cancer is an adaptable system, and the true test of the CoREST complex inhibition will be whether it can maintain its grip on aberrant megakaryocytes over years, not just weeks.

Nevertheless, the introduction of a fast-acting, oral medication that bypasses the traditional toxicity profiles of current second-line therapies represents a vital injection of hope. For the thousands of patients caught in the precarious gap between failing older drugs and the slow onset of newer biologics, JBI-802 offers a glimpse of a more precise, systemic solution to a deeply entrenched biological problem.